A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis
Wojciech Jurczak,Pier Luigi Zinzani,Georg Hess,Gianluca Gaidano,Mariano Provencio,Zsolt Nagy,Tadeusz Robak,Kami J. Maddocks,Christian Buske,Sumeet Ambarkhane,Wolfram Brugger,Maren Dirnberger-Hertweck,Sascha Tillmanns,Johannes Weirather,Kristie A. Blum